Concord Biotech Limited (CONCORDBIO.BO)
INR 1493.25
(-2.03%)
INR 1493.25
(-2.03%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | 2.67 Billion | 2.46 Billion | 2.07 Billion | 1.66 Billion | 1.54 Billion |
| Net Income | 3.08 Billion | 3.22 Billion | 2.37 Billion | 3.12 Billion | 2.13 Billion |
| Depreciation & Amortization | 535.91 Million | 540.33 Million | 500.5 Million | 275.23 Million | 212.45 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -811.79 Million | -522.83 Million | -220.53 Million | -887.63 Million | -217.24 Million |
| Other non-cash items | 1.79 Billion | -777.61 Million | -580.4 Million | -846.63 Million | -583.15 Million |
| Investing Cash Flow | -1.57 Billion | -1.57 Billion | -1.11 Billion | -1.95 Billion | -1.12 Billion |
| Investments in PPE | -856.88 Million | -1.45 Billion | -1.55 Billion | -2.04 Billion | -1.55 Billion |
| Acquisitions | 1.75 Million | 253 Thousand | 560 Thousand | - | 1.7 Million |
| Investment purchases | -8.38 Billion | -6.43 Billion | -5.21 Billion | -6.73 Billion | -4.81 Billion |
| Sales/Maturities of investments | 7.66 Billion | 6.24 Billion | 5.61 Billion | 6.82 Billion | 5.23 Billion |
| Other Investing Activities | -689.2 Million | 55.84 Million | 41.39 Million | 1.07 Million | 47 Thousand |
| Financing Cash Flow | -983.97 Million | -852.2 Million | -1 Billion | 311.24 Million | -434.16 Million |
| Debt repayment | -250.05 Million | -250 Million | -250.02 Million | -187.5 Million | -92.21 Million |
| Dividends payments | -714.52 Million | -535.63 Million | -705.21 Million | -57.06 Million | -805.45 Million |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | 13.91 Million | -66.57 Million | -46.41 Million | 555.8 Million | 463.5 Million |
| Accounts receivables | -786.59 Million | -430.97 Million | -527.69 Million | 65.01 Million | -295.36 Million |
| Accounts payables | -112.86 Million | 98.8 Million | 365.32 Million | -225.1 Million | 394.75 Million |
| Inventory | 43.6 Million | -172.28 Million | -415.09 Million | -423.77 Million | -195.14 Million |
| Other working capital | 44.05 Million | -18.38 Million | 356.93 Million | -303.77 Million | -121.48 Million |
| Cash at beginning of period | 34.99 Million | 6.67 Million | 51.44 Million | 24.08 Million | 37.59 Million |
| Cash at end of period | 470.24 Million | 34.99 Million | 6.67 Million | 51.44 Million | 24.08 Million |
| Capital Expenditure | -856.88 Million | -1.45 Billion | -1.55 Billion | -2.04 Billion | -1.55 Billion |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 435.25 Million | 28.32 Million | -44.77 Million | 27.36 Million | -13.51 Million |
| Free Cash Flow | 1.81 Billion | 1 Billion | 519.7 Million | -373.59 Million | -6.23 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 595.93 Million | 950.16 Million | 3.08 Billion | 775.72 Million | 810.19 Million | 544.94 Million |
| Depreciation & Amortization | - | - | 535.91 Million | 135.37 Million | 132.95 Million | 130.41 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | -811.79 Million | - | - | - |
| Other non-cash items | -595.93 Million | -950.16 Million | 1.79 Billion | -775.72 Million | -810.19 Million | -544.94 Million |
| Investing Cash Flow | - | - | -1.57 Billion | - | - | - |
| Investments in PPE | - | - | -856.88 Million | - | - | - |
| Acquisitions | - | - | 1.75 Million | - | - | - |
| Investment purchases | - | - | -8.38 Billion | - | - | - |
| Sales/Maturities of investments | - | - | 7.66 Billion | - | - | - |
| Other Investing Activities | - | - | -689.2 Million | - | - | - |
| Financing Cash Flow | - | - | -983.97 Million | - | - | - |
| Debt repayment | - | - | -250.05 Million | - | - | - |
| Dividends payments | - | - | -714.52 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | 13.91 Million | - | - | - |
| Accounts receivables | - | - | -786.59 Million | - | - | - |
| Accounts payables | - | - | -112.86 Million | - | - | - |
| Inventory | - | - | 43.6 Million | - | - | - |
| Other working capital | - | - | 44.05 Million | - | - | - |
| Cash at beginning of period | - | - | 34.99 Million | 60.78 Million | -749.41 Million | - |
| Cash at end of period | - | - | 470.24 Million | 775.72 Million | 60.78 Million | 544.94 Million |
| Capital Expenditure | - | - | -856.88 Million | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | 435.25 Million | 714.94 Million | 810.19 Million | 544.94 Million |
| Free Cash Flow | - | - | 1.81 Billion | 775.72 Million | 810.19 Million | 544.94 Million |
RAMCOSYS
CRISIL
SUPERHOUSE
PDRDF
5195
RGRNF